GRANT OF SHARE OPTIONS-RENALYTIX PLC

GRANT OF SHARE OPTIONS-RENALYTIX PLC

 

Grant of Share Options

 

LONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based careannounces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:

 

Name

Position

Options granted

Christopher Mills

Non-Executive Chairman

95,000

Daniel Levangie

Non-Executive Director

95,000

Chirag Parikh

Non-Executive Director

95,000

Catherine Coste

Non-Executive Director

95,000

 

The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023.  

 

All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors.

The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

No Comments

Post a Comment